Development and validation of the Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire in patients with Atrial Fibrillation

Circulation: Arrhythmia and Electrophysiology

Volumn 4, Issue 1, 2011, Pages 15-25

  Spertus, John ^a   Dorian, Paul ^b   Bubien, Rosemary ^c   Lewis, Steve ^d,g   Godejohn, Donna ^d   Reynolds, Matthew R ^e   Lakkireddy, Dhanunjaya R ^f   Wimmer, Alan P ^a   Bhandari, Anil ⁱ   Burk, Caroline ^d,h  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d St Jude Medical Inc USA   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f UNIVERSITY OF KANSAS HOSPITAL   (United States)

^g MDCC   (United States)

^h Outcomes Research Consultant   (United States)

ⁱ GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

Arrhythmia; Atrial fibrillation; Development; Health related quality of life; Questionnaire; Validation

Indexed keywords

ANTIARRHYTHMIC AGENT;

ABLATION THERAPY; ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION EFFECT ON QUALITY OF LIFE; CARDIAC PATIENT; CONSTRUCT VALIDITY; CONVERGENT VALIDITY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DIVERGENT VALIDITY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNAL CONSISTENCY; KNOWN GROUP VALIDITY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RATING SCALE; SHORT FORM 36; SYMPTOM; TEST RETEST RELIABILITY; TREATMENT RESPONSE; VALIDATION STUDY; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; QUESTIONNAIRE; REPRODUCIBILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 79953801219     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.110.958033     Document Type: Article

References (29)

1. Miyasaka Y, Barnes M, Gersh B, Cha S, Bailey K, Abhayaratna W, Seward J, Tsang T. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119-125. (Pubitemid 44420743)
2. Calkins H, Brugada J, Packer D, Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Natale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ. HRS/EHRA/ECAS Expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. Heart Rhythm. 2007;4: 816-861.
3. Coyne K, Margolis MK, Grandy S, Zimetbaum P. The state of patient-reported outcomes in atrial fibrillation: a review of current measures. Pharmacoeconomics. 2005;23:687-708. (Pubitemid 41007055)
4. Gronefeld G, Hohnloser S. Quality of life in atrial fibrillation: an increasingly important issue. Eur Heart J. 2003;5(suppl H):H25-H33. (Pubitemid 37229306)
5. Engelmann M, Godtfredsen J. Assessment of quality of life in pharmacological treatment of atrial fibrillation. Heart Drug. 2003;3:14-24. (Pubitemid 36831195)
6. Reynolds M, Ellis E, Zimetbaum P. Quality of life in atrial fibrillation: measurement tools and impact of interventions. J Cardiovasc Electro-physiol. 2007;19:762-768.
7. Braganca EOV, Luna Filho B, Maria VH, Levy D, de Paola A. Validating a new quality of life questionnaire for atrial fibrillation patients. Int J Cardiol. 2010;143:391-398.
8. Arribas F, Ormaetxe JM, Peinado R, Perulero N, Ramírez P, Badia X. Validation of the AF-QoL, a disease-specific quality of life questionnaire for patients with atrial fibrillation. Europace. 2010;12:364-370.
9. Patient-reported outcome measures: use in medical product development to support labeling claims. Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/ 06d-0044-gdl0001.pdf.
10. Spertus J. Evolving applications for patient-centered health status measures. Circulation. 2008;118:2103-2110.
11. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): conceptual framework and item selection. Med Care. 1992;30: 473-483.
12. Brooks R, Rabin R, de Charro F, editors. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective-Evidence from the EuroQol BIOMED Research Program. The Netherlands: Kluwer; 2003; p 299.
13. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers G, CamM J, Masood A, Luderitz B. The impairment of health-related quality of life in patients with intermittent AF: implications for the assessment of investi-gational therapy. J Am Coll Cardiol. 2000;36:1303-1309.
14. Bubien R, Kay G, Jenkins L. Test Specifications for Symptoms Checklist: Frequency and Severity. Milwaukee, WI: University of Wisconsin; 1993.
15. Spitzer RL, Kroenke K, Williams JB, Löwe B. The GAD-7 scale was accurate for diagnosing generalised anxiety disorder: a brief measure for assessing generalised anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092-1097.
16. Jaeschke R, Singer J, Guyatt G. Measurement of health status: ascertaining the minimal clinically important difference Control. Clin Trials. 1989;10:407-415. (Pubitemid 20025670)
17. Juniper EF, Guyatt GH, Willan A, Griffith L. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47:81-87. (Pubitemid 24034293)
18. Kaiser F. The application of electronic computers to factor analysis. Educ Psychol Meas. 1960;20:141-151.
19. Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to their Development and Use. 2nd ed. New York: Oxford University Press; 1995:65.
20. Hays R, Revicki DA. Reliability and validity (including responsiveness). In: Fayers P, Hays R, editors. Assessing Quality of Life in Clinical Trials. 2nd edition. New York: Oxford University Press; 2005.
21. Terwee C, Dekker F, Wiersinga W, Prummel M, Bossuyt P. On assessing responsiveness of health-related quality of life instruments: guidelines for instrument evaluation. Qual Life Res. 2003;12:349-362. (Pubitemid 36612040)
22. Kazis L, Anderson J, Meenan R. Effect sizes for interpreting changes in health status. Med Care. 1989;27(suppl 3):S178-S189.
23. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
24. Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D, Kanagaratnam L, Heddle W, Leitch J, Perks A, Ferguson L, Bulsara M. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol. 2003;41:1696-1702.
25. Dorian P, Paquette M, Newman D, Green M, Connolly SJ, Talajic M, Roy D. Quality-of-life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J. 2002;143:984-990. (Pubitemid 34666888)
26. Spertus J, Peterson E, Conard M, Heidenreich P, Krumholz H, Jones P, McCullough P, Pina I, Tooley J, Weintraub W, Rumsfeld J. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J. 2005;150:707-715. (Pubitemid 41396503)
27. Spertus J, Winder J, Dewhurst T, Deyo R, Fihn S. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol. 1994;74: 1240-1244. (Pubitemid 24375015)
28. Harden M, Nystrom B, Kulich K, Carlsson J, Bengtson A, Edvardsson N. Validity and reliability of a new, short symptom rating scale in patients with persistent atrial fibrillation. Health Qual Life Outcomes. 2009;7:65.
29. Ogawa S, Yamashita T, Yamazaki T. Optimal treatment strategy for patients with paroxysmal atrial fibrillation J-RHYTHM Study. Circulation. 2009;73:242-248.